NYSE:AZN • US0463531089
We assign a fundamental rating of 6 out of 10 to AZN. AZN was compared to 191 industry peers in the Pharmaceuticals industry. AZN has an excellent profitability rating, but there are some minor concerns on its financial health. AZN has a correct valuation and a medium growth rate. AZN also has an excellent dividend rating.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROIC | 13.63% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Altman-Z | 3.97 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.03 | ||
| Fwd PE | 19.2 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.57 | ||
| EV/EBITDA | 17.23 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.64% |
204.52
-0.24 (-0.12%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.64% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.03 | ||
| Fwd PE | 19.2 | ||
| P/S | 5.4 | ||
| P/FCF | 36.57 | ||
| P/OCF | 21.75 | ||
| P/B | 6.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 17.23 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROCE | 16.8% | ||
| ROIC | 13.63% | ||
| ROICexc | 14.63% | ||
| ROICexgc | 59.47% | ||
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% | ||
| FCFM | 14.76% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 103% | ||
| Cap/Sales | 10.05% | ||
| Interest Coverage | 10.65 | ||
| Cash Conversion | 73.79% | ||
| Profit Quality | 84.79% | ||
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 3.97 |
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 25.03 and the Price/Book (PB) ratio is 6.51.
The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 30.41% in the next year.